Anticholinergics

Anticholinergics has been studied in 91 papers since 2016: 62 observational studies in people, 26 reviews; 25 in the past year. The newest story, Oct 4, 2026: “Anticholinergics link to higher dementia risk in older women”.

Intervention

91 papers study it85 findingsUpdated

4 new papers in 30 daysSee all 91 papers on anticholinergics

At a glance

Anticholinergic use is linked with cognitive impairment, falls and mortality in human observational studies, with independent labs reporting these associations again. Dementia links vary, and a study links use with lower mortality in people with dementia receiving antidepressants. Some papers declare company ties.

85 findings in 58 papers from 2016 to 2026, 8 of them since April 2026

Independent labs found the same change in people. 47 independent labs in 20 countries; 2 trials, none about aging.

“individuals with anticholinergic drugs prescribed had significantly higher odds of being diagnosed with dementia (adjusted odds ratio, 1.50 [95% confidence interval, 1.47-1.54]).”
Association of anticholinergic drug exposure with the risk of dementia among older adults in Japan: The LIFE StudyInternational journal of geriatric psychiatry2023doi:10.1002/gps.6029

5 of its findings point the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 47 independent labs in 20 countries
  • 5 findings against
  • 2 trials, none about aging
  • Funders: National Institute on Aging and others
  • 10 of 73 findings with company ties
  • Humans62
  • In silico1

What did studies of anticholinergics find?

18

Studies of anticholinergics measured 18 outcomes; the most studied is cognitive function (7 studies).

Cognitive function

downin humans7

7 studies
  1. Anticholinergics are linked with worse cognitive function in neuropsychiatric unit patients (r = -0.178, p = 0.039).

    “The correlation between ACB burden and MMSE was negative and significant (r = -0.178; p = 0.039)”

    Humansin neuropsychiatric unit patientsn = 135

    [Translated article] Anticholinergic burden and its relationship with cognitive impairment in a neuropsychiatric unit

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

  2. Anticholinergics are linked with worse cognitive function in humans (Alzheimer's disease spectrum) (CV-BF = 9.0).

    “moderate evidence for an association of anticholinergic burden with baseline levels of cognitive impairment for the PACC5 as a global cognitive function score (CV-BF = 9.0)”

    HumansAlzheimer's disease spectrumn = 794

    Associations of anticholinergic burden of medication with cognitive decline and longitudinal brain atrophy in the Alzheimer's disease spectrum

    Frontiers in aging neuroscience

  3. Anticholinergics are linked with worse cognitive function in humans (-1.74 and -1.70/year vs -1.26/year, p < 0.01).

    “MMSE decrease was steeper in patients with moderate and high Drug Burden Index ( -1.74 and -1.70/year, respectively) than in patients with no exposure (-1.26/year)”

    Humansafter adjusting for age, education, anxiety and depressive disorders, functional autonomy, and behavioural disorders

    Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study

    Alzheimer's research & therapy

  4. Anticholinergics are linked with worse cognitive function in humans (older patients with cognitive concerns) (r = -0.106, p = 0.037).

    “ACB scores were negatively correlated with AP (r = -0.106, p = 0.037).”

    Humansolder patients with cognitive concernsn = 392

    Anticholinergic and sedative medication use in older patients with cognitive concerns

    Journal of the American Geriatrics Society

  5. Anticholinergics are linked with worse cognitive function in humans (higher ACB (>3) scores) (p = <0.001).

    “those with higher ACB showing more rapid cognitive decline over time”

    Humanshigher ACB (>3) scoresn = 20,575

    Longitudinal associations of anticholinergic medications on cognition and possible mitigating role of physical activity

    Journal of the American Geriatrics Society

  6. Anticholinergics are linked with worse cognitive function in humans (β = -0.21, 95% CI [-0.36; -0.05]).

    “Anticholinergic use was associated with lower cognitive global cognition (β= -0.21; 95% CI [-0.36; -0.05])”

    Humansaverage 7-year follow upn = 6,249

    Anticholinergic Drug Burden and Neurocognitive Performance in the Study of Latinos-Investigation of Neurocognitive Aging

    Journal of Alzheimer's disease : JAD

  7. Anticholinergics impair cognitive function in humans.

    “they can also cause central effects such as cognitive impairment”

    Review

    Anticholinergic action is rarely a good thing

    Therapeutic advances in psychopharmacology

Mortality

no changein humans1

1 study
  1. Anticholinergics were not clearly linked with mortality in humans (emergency laparotomy).

    “There was no significant difference in mortality up to 1 year following surgery between those with or without polypharmacy, nor those with or without significant ACB.”

    Humansemergency laparotomyn = 144

    Polypharmacy and anticholinergic burden are common but not independently associated with outcomes after emergency laparotomy in older adults

    Langenbeck's archives of surgery

Brain atrophy

no changein humans1

1 study
  1. Anticholinergics were not clearly linked with brain atrophy in humans (Alzheimer's disease spectrum).

    “anticholinergic burden had only a modest effect on cognitive decline and no effect on atrophy in brain regions that are related to the cholinergic system.”

    HumansAlzheimer's disease spectrumn = 703

    Associations of anticholinergic burden of medication with cognitive decline and longitudinal brain atrophy in the Alzheimer's disease spectrum

    Frontiers in aging neuroscience

Executive function

downin humans1

1 study
  1. Anticholinergics are linked with worse executive function in humans (Alzheimer's disease spectrum) (CV-BF = 2.5).

    “weak evidence for an association of anticholinergic burden with longitudinal rates of change in the trail-making test B as an executive function score (CV-BF = 2.5)”

    HumansAlzheimer's disease spectrumn = 794

    Associations of anticholinergic burden of medication with cognitive decline and longitudinal brain atrophy in the Alzheimer's disease spectrum

    Frontiers in aging neuroscience

Gait disturbances

upin humans1

1 study
  1. Anticholinergics increase gait disturbances in humans.

    “Medications, particularly anticholinergics and polypharmacy, further contribute to gait disturbances, compounding falls risk.”

    Review

    Walking through aging: A review of gait laboratory-based assessments and geriatric syndromes

    The Journal of frailty & aging

Grip strength

downin humans1

1 study
  1. Anticholinergics are linked with worse grip strength in humans (6-year WCE model, per 1-unit increase in weighted mSDD) (MD per year, -0.0329 [95% CI -0.0612 to -0.0046] kg).

    “the 6-year WCE model had the lowest QIC (MD per year, -0.0329 [95% CI -0.0612 to -0.0046] kg).”

    Humans6-year WCE model, per 1-unit increase in weighted mSDDn = 4,200

    Cumulative Anticholinergic Exposure and Change in Gait Speed and Grip Strength in Older Adults

    JAMA network open

Gait speed

downin humans1

1 study
  1. Anticholinergics are linked with worse gait speed in humans (10-year TSDD 1096 or greater vs nonusers) (MD per year, -0.0132 [95% CI, -0.0193 to -0.0070] m/s).

    “Compared with nonusers, a greater decline rate in gait speed was found for those with 10-year TSDD 1096 or greater (MD per year, -0.0132 [95% CI, -0.0193 to -0.0070] m/s)”

    Humans10-year TSDD 1096 or greater vs nonusers8.2 years of follow-upn = 4,210

    Cumulative Anticholinergic Exposure and Change in Gait Speed and Grip Strength in Older Adults

    JAMA network open

Self-reported cognitive difficulties

upin humans1

1 study
  1. Anticholinergics are linked with higher self-reported cognitive difficulties in humans (high burden) (β = 3.89, 95% CI: 1.08, 6.71).

    “High anticholinergic burden was linked to worse cognitive ability [ β = -3.81; 95% confidence interval (CI): -7.16, -0.46] and SCD ( β = 3.89; 95% CI: 1.08, 6.71).”

    Humanshigh burdenn = 824

    Cognitive impact of anticholinergic and sedative burden in people with HIV

    AIDS (London, England)

Cognitive ability

downin humans1

1 study
  1. Anticholinergics are linked with worse cognitive ability in humans (high burden) (β = -3.81, 95% CI: -7.16, -0.46).

    “High anticholinergic burden was linked to worse cognitive ability [ β = -3.81; 95% confidence interval (CI): -7.16, -0.46]”

    Humanshigh burdenn = 824

    Cognitive impact of anticholinergic and sedative burden in people with HIV

    AIDS (London, England)

Alzheimer's disease or related dementias onset

no changein humans1

1 study
  1. Anticholinergics were not clearly linked with Alzheimer's disease or related dementias onset in humans (Prostate cancer; regardless of primary treatment modality) (P = .06).

    “PDE5i (P = .07) and AC (P = .06) were not associated with dementia regardless of primary treatment modality.”

    HumansProstate cancer; regardless of primary treatment modalityMedian use 12.2 monthsmalesn = 5,937

    Association Between Common Urologic Medications and Onset of Alzheimer's Disease and Related Dementias in Men With Prostate Cancer Managed by Different Primary Treatment Modalities

    Urology

More on Alzheimer's disease or related dementias onset

All 18

What is anticholinergics linked with?

24

Studies link anticholinergics with 24 measures, most often dementia (14 studies), mortality (10) and falls (6).

Dementia

upin humans14HR 1.006–1.52

14 studies
  1. Anticholinergics are linked with a higher risk of dementia in humans (vs. beta-3 agonists only, adjusted for age, sex, comorbidities, and psychotropic drug use) (OR 1.53, 95% CI 1.10-2.14).

    “The adjusted odds ratio (OR) and 95% confidence interval (CI) for OAB anticholinergics were 1.53 (95% CI: 1.10-2.14, p = 0.0110)”

    Humansvs. beta-3 agonists only, adjusted for age, sex, comorbidities, and psychotropic drug use

    Associations between Anticholinergic Use and Dementia Risk in a Prevalent-User Cohort: Analysis of Japanese Medication Histories as Real-World Data

    Biological & pharmaceutical bulletin

  2. Anticholinergics are linked with a higher risk of dementia in humans (adjusted models) (median OR 1.09-1.10 vs 1.05-1.06).

    “Odds ratios for death, dementia, and delirium using anticholinergic-polypharmacy pseudoscales (median = 1.09-1.10) were greater than those of general-polypharmacy pseudoscales (1.05-1.06).”

    Humansadjusted models

    A simulation study comparing anticholinergic drug use with polypharmacy for risk of death, dementia, and delirium in UK Biobank

    The journals of gerontology. Series A, Biological sciences and medical sciences

  3. Anticholinergics are linked with a higher risk of dementia in humans (older surgical patients after major surgery) (HR 1.006; 95% CI 1.003-1.008).

    “Each one-order increase in inpatient anticholinergic medications was associated with a 0.60% increase in dementia risk (HR 1.006; 95% CI 1.003-1.008).”

    Humansolder surgical patients after major surgery

    Perioperative Anticholinergic Medication Use and Incident Dementia among Older Surgical Patients: a Retrospective Cohort Study using Real-World Data

    Drugs & aging

  4. Anticholinergics are linked with a higher risk of dementia in humans (overactive bladder) (aHR 1.22, 95% CI 1.15-1.30).

    “there was an increased risk of dementia in the anticholinergic drug group compared to the beta-3 agonist group (adjusted hazard ratio [aHR] = 1.22; 95% confidence interval [CI], 1.15-1.30).”

    Humansoveractive bladder

    Risks of Dementia Associated With Anticholinergic Medication Compared to Beta-3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study

    International journal of geriatric psychiatry

  5. Anticholinergics are linked with a higher risk of dementia in humans (adjusted odds ratio 1.18 (95% CI 1.16 to 1.20)).

    “The adjusted odds ratio for dementia associated with the use of any anticholinergic drug used to treat an overactive bladder was 1.18 (95% confidence interval (CI) 1.16 to 1.20)”

    Humans

    Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study

    BMJ medicine

  6. Anticholinergics are linked with a higher risk of dementia in humans (relative to those with no exposure) (OR 2.7, 95% CI 2.2-3.3).

    “high doses of anticholinergic medications were associated with increased odds of dementia at 1 y relative to those with no exposure (odds ratio 2.7; 95% confidence interval 2.2-3.3)”

    Humansrelative to those with no exposuresix or more dosesduring hospital stayn = 39,665

    A Mediation Analysis Examining High Risk, Anticholinergic Medication Use, Delirium, and Dementia After Major Surgery

    The Journal of surgical research

  7. Anticholinergics are linked with a higher risk of dementia in humans (aOR 1.50 (95% CI 1.47-1.54)).

    “individuals with anticholinergic drugs prescribed had significantly higher odds of being diagnosed with dementia (adjusted odds ratio, 1.50 [95% confidence interval, 1.47-1.54]).”

    Humans

    Association of anticholinergic drug exposure with the risk of dementia among older adults in Japan: The LIFE Study

    International journal of geriatric psychiatry

  8. Anticholinergics are linked with a higher risk of dementia in humans (1.6 to 2.6 times increased risk (95% CI 1.4-1.9 to 1.1-6.3)).

    “ACH exposure to one, two, three and four or more ACH medications was associated with a 1.6 (95% CI 1.4-1.9), 2.1 (95% CI 1.7-2.8), 2.6 (95% CI 1.5-4.4), and 2.6 (95% CI 1.1-6.3) times, respectively, increased risk of a dementia/Alzheimer's disease diagnosis”

    Humans

    Anticholinergic exposure and its association with dementia/Alzheimer's disease and mortality in older adults

    BMC geriatrics

  9. Anticholinergics are associated with dementia in humans.

    “the total ACB score ≥ 1 was significantly associated with dementia”

    Humansn = 329

    Anticholinergic Burden of Geriatric Ward Inpatients

    Medicina (Kaunas, Lithuania)

  10. Anticholinergics are associated with dementia in humans (Patients with overactive bladder without baseline cognitive impairment) (HR 1.52 (95% CI 1.29–1.80); nonlinear inverted U-shaped relationship, peaking at approximately 874 cumulative defined daily dose (HR 1.63, 95% CI 1.32–2.00)).

    “ACH use was associated with significantly increased dementia risk (HR: 1.52; 95% CI: 1.29-1.80).”

    ReviewPatients with overactive bladder without baseline cognitive impairmentn = 7,891,574

    Nonlinear dose-response relationship between cumulative anticholinergic use and the risk of dementia in adults with overactive bladder: a systematic review and dose-response meta-analysis

    Age and ageing

All 14

More on Dementia

Mortality

upin humans9no changein humans1downin humans1OR 1.09–2.5

10 studies
  1. Anticholinergics are linked with a higher risk of mortality in humans (adjusted models) (median OR 1.09-1.10 vs 1.05-1.06).

    “Odds ratios for death, dementia, and delirium using anticholinergic-polypharmacy pseudoscales (median = 1.09-1.10) were greater than those of general-polypharmacy pseudoscales (1.05-1.06).”

    Humansadjusted models

    A simulation study comparing anticholinergic drug use with polypharmacy for risk of death, dementia, and delirium in UK Biobank

    The journals of gerontology. Series A, Biological sciences and medical sciences

  2. Anticholinergics are linked with a higher risk of mortality in humans (post discharge) (hazard ratio: 2.98, 95% confidence interval (0.96-9.28)).

    “an ACB score of ≥ 3 at discharge was marginally associated with one-year mortality post discharge [hazard ratio: 2.98, 95% confidence interval (0.96-9.28)].”

    Humanspost discharge1 yearn = 290

    Anticholinergic burden and clinical outcomes among older adults admitted in a tertiary hospital: a prospective cohort study

    PloS one

  3. Anticholinergics are linked with a higher risk of mortality in humans (1.4 to 3.8 times increased risk (95% CI 1.2-1.6 to 2.6-5.4)).

    “ACH exposure to one, two, three and four or more medications was associated with a 1.4 (95% CI 1.2-1.6), 2.6 (95% CI 2.1-3.3), 3.8 (95% CI 2.6-5.4), and 3.4 (95% CI 1.8-6.4) times, respectively, increased risk of mortality”

    Humans

    Anticholinergic exposure and its association with dementia/Alzheimer's disease and mortality in older adults

    BMC geriatrics

  4. Anticholinergics are linked with a higher risk of mortality in humans (hip fracture surgery) (OR 2.5 (CI: 2.0-3.1)).

    “The 30-day mortality increased from 7% for patients with ACB score of 0 to 16% for patients with ACB score of ≥5, corresponding to an adjusted OR 2.5 (CI: 2.0-3.1).”

    Humanship fracture surgery90 days before surgeryn = 31,443

    Association of anticholinergic drug use with postoperative mortality among patients with hip fracture. A nationwide cohort study

    Archives of gerontology and geriatrics

  5. Anticholinergics are associated with mortality in patients with dementia receiving antipsychotics (HR 0.91; 95% CI 0.82-1.02; p = 0.105).

    “but not the antipsychotic one (HR: 0.91; 95% CI: 0.82-1.02; p = 0.105)”

    Humansin patients with dementia receiving antipsychotics

    Centrally-acting anticholinergic drugs- associations with mortality, hospitalisation and cognitive decline following dementia diagnosis in people receiving antidepressant and antipsychotic drugs

    Aging & mental health

  6. Anticholinergics are linked with a lower risk of mortality in patients with dementia receiving antidepressants (HR 0.88; 95% CI 0.79-0.98; p = 0.023).

    “There was a reduced mortality risk in people receiving agents with high central anticholinergic burden compared to those with no or low burden which was statistically significant in the antidepressant cohort”

    Humansin patients with dementia receiving antidepressants

    Centrally-acting anticholinergic drugs- associations with mortality, hospitalisation and cognitive decline following dementia diagnosis in people receiving antidepressant and antipsychotic drugs

    Aging & mental health

  7. Anticholinergics are associated with mortality in humans (OR 1.52, 95% CI 1.23-1.88).

    “as were anticholinergics (OR, 1.52; 95% CI, 1.23-1.88).”

    Review

    Association between Potentially Inappropriate Medication and Mortality Risk in Older Adults: A Systematic Review and Meta-Analysis

    Journal of the American Medical Directors Association

  8. Anticholinergics raise the risk of mortality in humans.

    “they have consistently been linked with an increased risk of dementia and death in older people.”

    Review

    Anticholinergic action is rarely a good thing

    Therapeutic advances in psychopharmacology

  9. Anticholinergics are associated with mortality in humans.

    “long-term use of medicines with anticholinergic activity is associated with worsening of cognitive function, increased incidence of dementia and increased mortality”

    Reviewlong-term

    Managing drugs with anticholinergic activity

    Drug and therapeutics bulletin

  10. Anticholinergics raise the risk of mortality in humans (frailty).

    “Observed associations included reduced ability for chair standing, slower gait speeds, poorer physical performance, increased risk of falls and mortality.”

    Reviewfrailty

    Associations Between Anticholinergic Medication Exposure and Adverse Health Outcomes in Older People with Frailty: A Systematic Review and Meta-analysis

    Drugs - real world outcomes

All 11

Falls

upin humans6OR 1.412–1.86

6 studies
  1. Anticholinergics are linked with a higher risk of falls in humans (older adults with intellectual disability) (OR = 1.86, 95% CI: 1.03-3.38).

    “Mild and high ACB scores at time point 1 were significantly associated with a higher risk of falls (odds ratio [OR] = 1.86, 95% CI: 1.03-3.38)”

    Humansolder adults with intellectual disability10 yearsn = 487

    Ten-Year Outcomes of Anticholinergic Use Among Older Adults With Intellectual Disability: Findings From the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS-TILDA)

    Journal of intellectual disability research : JIDR

  2. Anticholinergics are associated with falls in humans (baseline) (OR 1.412, 95% CI 1.035-1.926).

    “Logistic regression revealed an independent association between ACB 1-2 and falls at baseline (odds ratio, OR (95% confidence interval, CI) =1.412(1.035-1.926))”

    HumansbaselineACB scores of 1-2n = 1,499

    A five-year prospective evaluation of anticholinergic cognitive burden and falls in the Malaysian elders longitudinal research (MELoR) study

    Archives of gerontology and geriatrics

  3. Anticholinergics are associated with falls in humans (dementia inpatients) (IRR 2.2, P < .001).

    “Patient fall rate was significantly associated with anticholinergic drug use (Incidence rate ratio: 2.2; P < .001)”

    Humansdementia inpatients

    A delicate balance: Psychotropic polypharmacy and anti-cholinergic use are correlated with fall incidence in Australian inpatients with dementia

    Aging medicine (Milton (N.S.W))

  4. Anticholinergics raise the risk of falls in humans.

    “higher cumulative anticholinergic burden is associated with increased risks of cognitive impairment, delirium, falls, functional decline, and possibly dementia.”

    Review

    Polypharmacy and the Ageing Brain: Anticholinergic Burden in the Ageing Population and the Impact of Gynaecological Medications

    Preprints.orgPreprint

  5. Anticholinergics raise the risk of falls in humans.

    “Anticholinergic side effects include muscle weakness, blurred vision, and mental confusion which are likely to lead to increased falls risk.”

    Review

    Anticholinergics and falls in older adults

    Expert review of clinical pharmacology

  6. Anticholinergics are associated with falls in humans.

    “The evidence supports an association between moderate to high ACB and risk of falling in older people”

    Review

    Anticholinergic burden measures and older people's falls risk: a systematic prognostic review

    Therapeutic advances in drug safety

Cognitive impairment

upin humans3downin humans1OR 1.26–2.36

4 studies
  1. Anticholinergics are linked with a higher risk of cognitive impairment in neuropsychiatric unit patients (OR = 2.36, 71.7% vs 51.7%).

    “Among those exposed to high burden, 71.7% presented impairment vs. 51.7% exposed to low-moderate burden (χ2 = 4.13; p = 0.042; OR = 2.36).”

    Humansin neuropsychiatric unit patientsn = 135

    [Translated article] Anticholinergic burden and its relationship with cognitive impairment in a neuropsychiatric unit

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

  2. Anticholinergics are linked with a higher risk of cognitive impairment in humans (OR = 1.26, 95% CI 1.01-1.58).

    “Higher odds of cognitive impairment were observed among ACH users compared with the nonusers (OR = 1.26, 95% CI 1.01-1.58).”

    Humansn = 13,623

    Disparities in Cognitive Impairment With Anticholinergic Drug Use: A Population-Based Study

    Neurology. Clinical practice

  3. Anticholinergics raise the risk of cognitive impairment in humans.

    “higher cumulative anticholinergic burden is associated with increased risks of cognitive impairment, delirium, falls, functional decline, and possibly dementia.”

    Review

    Polypharmacy and the Ageing Brain: Anticholinergic Burden in the Ageing Population and the Impact of Gynaecological Medications

    Preprints.orgPreprint

  4. Anticholinergics are associated with cognitive impairment in humans.

    “Current evidence linking medicines with anticholinergic activity and cognitive impairment is derived mostly from observational data.”

    Review

    Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research

    Drugs & aging

More on Cognitive impairment

Bone fracture

upin humans2OR 1.17

2 studies
  1. Anticholinergics are linked with a higher risk of bone fracture in humans (OR 1.17, 95% CI: 1.01–1.36).

    “The odds of any fracture were higher among those with anticholinergic burden ≥ 3 (OR, 1.17; 95% CI: 1.01–1.36)”

    Humansup to 5 yearsn = 32,771

    Duration of anticholinergic burden and polypharmacy and the risk of fractures in older Korean adults: a nationwide cohort study

    BMC geriatrics

  2. Anticholinergics raise the risk of bone fracture in humans (regardless of the anticholinergic burden scale used) (pooled RR 1.28, 95% CI 1.18-1.39).

    “Meta-analysis indicated a positive relationship between use of anticholinergic drugs and fracture risk, regardless of the anticholinergic burden scale used.”

    Reviewregardless of the anticholinergic burden scale usedn = 487,247

    A meta-analysis of observational studies on anticholinergic burden and fracture risk: evaluation of conventional burden scales

    Journal of pharmaceutical health care and sciences

More on Bone fracture

Delirium

upin humans2OR 1.09–1.1

2 studies
  1. Anticholinergics are linked with a higher risk of delirium in humans (adjusted models) (median OR 1.09-1.10 vs 1.05-1.06).

    “Odds ratios for death, dementia, and delirium using anticholinergic-polypharmacy pseudoscales (median = 1.09-1.10) were greater than those of general-polypharmacy pseudoscales (1.05-1.06).”

    Humansadjusted models

    A simulation study comparing anticholinergic drug use with polypharmacy for risk of death, dementia, and delirium in UK Biobank

    The journals of gerontology. Series A, Biological sciences and medical sciences

  2. Anticholinergics are linked with a higher risk of delirium in humans (continuous usage compared to beta-3 agonist users) (HR 1.13, 95% CI 1.02-1.26).

    “With continuous usage, there was an increased HR of delirium among users of newer anticholinergics (HR 1.13, 95% CI 1.02-1.26)”

    Humanscontinuous usage compared to beta-3 agonist userscontinuous usagen = 103,024

    The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications

    Neurourology and urodynamics

More on Delirium

Frailty

upin humans2

2 studies
  1. Anticholinergics are associated with frailty in humans (urinary incontinence) (r=0.728, p<0.01).

    “A strong, positive, and significant correlation was found between anticholinergic burden and frailty (r=0.728, p<0.01).”

    Humansurinary incontinencen = 197

    The relationship between anticholinergic drug burden and clinical frailty in urinary incontinence patients

    Revista da Associacao Medica Brasileira (1992)

  2. Anticholinergics are associated with frailty in humans (r = 0.30 to 0.47, p < 0.001).

    “ACB was positively correlated with frailty for all groups (r = 0.30 to 0.47, p < 0.001).”

    Humans12 months

    The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies

    Alzheimer's & dementia (Amsterdam, Netherlands)

Cognitive function

downin humans1mixedin humans1

2 studies
  1. Anticholinergics are associated with cognitive function in humans.

    “long-term use of medicines with anticholinergic activity is associated with worsening of cognitive function”

    Reviewlong-term

    Managing drugs with anticholinergic activity

    Drug and therapeutics bulletin

  2. Anticholinergics are associated with cognitive function in humans (pre-existing dementia).

    “Inconsistent findings were reported for cognitive function (in 4 studies) and neuropsychiatric functions (in 2 studies).”

    Reviewpre-existing dementia

    Anticholinergics and clinical outcomes amongst people with pre-existing dementia: A systematic review

    Maturitas

Mild behavioral impairment

upin humans1HR 1.07

1 study
  1. Anticholinergics are associated with mild behavioral impairment in humans (p ≤0.001).

    “Higher maximum total ACB score was associated with a higher likelihood of developing MBI (p ≤0.001).”

    Humans5.64 yearsn = 4,865

    The Impact of Anticholinergic Burden on the Development of Mild Behavioral Impairment

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

  2. Anticholinergics are linked with a higher risk of mild behavioral impairment in humans (adjusted for 10-year mortality risk, age, sex, education, and race) (HR 1.07, 95% CI 1.02-1.14).

    “When assessed as a time varying covariate, ACB score was associated with incident MBI (HR 1.07, 95% CI 1.02-1.14, p = 0.010).”

    Humansadjusted for 10-year mortality risk, age, sex, education, and race5.64 yearsn = 4,865

    The Impact of Anticholinergic Burden on the Development of Mild Behavioral Impairment

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

More on Mild behavioral impairment

30-day mortality

no changein humans1

1 study
  1. Anticholinergics are associated with 30-day mortality in a 48-hour landmark analysis (RD -0.33 percentage points, 95% CI -7.90 to 5.38).

    “The direct overlap-weighted risk difference was − 0.33 percentage points (95% CI -7.90 to 5.38)”

    Humansin a 48-hour landmark analysisn = 1,455

    Early strong anticholinergic initiation and 30-day mortality in older inpatients with dementia: a target trial emulation

    Research SquarePreprint

All 24

Has anticholinergics been tested in people?

0 of 2 about aging

Yes: 62 observational studies in people have been published, and 2 trials are registered.

In trials

Trial sponsors

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 1Mar 2026: 2Apr 2026: 3May 2026: 4Jun 2026: 2Jul 2026: 0Aug 2026: 3Sep 2026: 2Oct 2026: 2Nov 2026: 224 papers in 12 months
International Journal of Urology

Anticholinergics link to higher dementia risk in older women

Anticholinergic use was associated with higher incident dementia risk compared with β3-agonist use (hazard ratio, 1.49; 95% CI, 1.04–2.13).Anticholinergic use was associated with higher incident dementia risk compared with β3-agonist use (hazard ratio, 1.49; 95% CI, 1.04–2.13).

Cohort study of 2,189 peopleDementia
Autism Research

Some medicines linked to memory problems in autistic adults

Caregiver surveys of 512 autistic adults with higher support needs linked higher anticholinergic medication scores to memory problems and changes associated with…Caregiver surveys of 512 autistic adults with higher support needs linked higher anticholinergic medication scores to memory problems and changes associated with cognitive decline.

Cross-sectional · 467 peoplePopulations

See all 91 papers on anticholinergics